NOVAVAX INC Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31)
NOVAVAX INC (NVAX) had Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) of $36.37 million as of 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesFairValueDisclosure · last filed 2013-05-09
- 2013-03-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $36.37M.
- 2012-12-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $32.95M.
- 2012-09-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $17.67M.
- 2012-06-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $11.20M.
| Period end | Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) |
|---|---|
| 2013-03-31 | $36.37M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $32.95M 10-Q · filed 2013-05-09 |
| 2012-09-30 | $17.67M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $11.20M 10-Q · filed 2012-08-09 |
| 2011-12-31 | $4.21M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |